Piper Jaffray and Co

Piper Jaffray analyst Ian Somaiya noted in a research report last week that "the Breo...After the approval, Piper Jaffray's Somaiya reiterated his rating on Theravance's shares

As Piper Jaffray analyst Ian Somaiya noted in a research report last month, there is "still no visibility into what went wrong," and neither Affymax nor Takeda has offered a timeline for concluding the investigation

In a research note last month, Piper Jaffray analyst Charles Duncan wrote that it "is likely to be something of a moving target in advance of launch

Shares/ Units (M) Price Shares Out (M)@ Lead, Other Underwriters Gross (US$M) Post- Offering Market Cap (M)% INITIAL OFFERINGS Chimerix Inc. (Research Triangle Park, N.C.; CMRX)1 3/8/13 4/11/13 7.32S $14 24.4 Morgan Stanley Cowen & Co. (co-lead) William Blair Lazard Capital Markets $102.5 $341.6 Omthera Pharmaceuticals Inc. (Princeton, N.J.; OMTH)2 3/8/13 4/12/13 8S $8 24.4 BofA Merrill Lynch Barclays (co-lead) Leerink Swann (co-lead) Stifel Piper Jaffray $64 $195.2 Tetraphase

Piper Jaffray analyst Edward Tenthoff anticipates launch this quarter, with Woodcliff Lake, N.J.-based Eisai hosting a sales force of about 200 representatives...With the anticipated launch milestone from Eisai, Piper Jaffray's Tenthoff said the firm should have "sufficient cash to reach profitability

Piper Jaffray & Co

BofA Merrill Lynch, Barclays and Leerink Swann acted as joint book-running managers, while Stifel and Piper Jaffray served as co-managers. (See BioWorld Today, April 2, 2013.)

Piper Jaffray's Somaiya was more optimistic

BofA Merrill Lynch, Barclays and Leerink Swann acted as joint book-running managers for the offering, with Stifel and Piper Jaffray serving as co-managers

Piper Jaffray analyst Charles Duncan wrote in a research report that pimavanserin may not only "become the 'go to' drug" in PDP, but has a shot at the larger ADP market

IND on the Horizon Piper Jaffray and Co

Shares/ Units (M) Price Shares Out (M)@ Lead, Other Underwriters Gross (US$M) Post- Offering Market Cap (M)% FOLLOW-ON OFFERINGS Achillion Pharmaceuticals Inc. (New Haven, Conn.; ACHN)3 11/21/12 3/1/13 16.9S $8.40 96.6 Citigroup Leerink Swann (co-lead) JMP Securities LLC Piper Jaffray & Co...MLV & Co. $60 GW Pharma plc (Porton Down, UK; GWPH) 3/19/13 ADSs N/A N/A Lazard Capital Markets Cowen & Co. (co-lead) Canaccord Genuity Roth Capital Partners $50 Omthera Pharmaceuticals Inc

Piper Jaffray's Ian Somaiya pointed out that there was no significant imbalance in infections (60 percent on Tecfidera and 58 percent on placebo) or serious infections (2 percent and 2 percent, respectively) in the Phase III trials

Alexion Pharmaceuticals Inc., of Cheshire, Conn., received a warning letter from the FDA regarding manufacturing issues with Soliris (eculizumab) for paroxysmal nocturnal hemoglobinuria, but Piper Jaffray analyst Ian Somaiya downplayed the news, suggesting that investors buy Alexion on weakness caused by the disclosure

The good news, wrote Piper Jaffray analyst Charles Duncan in a research report, is that costs for Ziopharm will likely drop

Piper Jaffray analyst Ian Somaiya weighed in, too, noting that about 76,000 new cases of melanoma cropped up in the U.S

Piper Jaffray is serving as the underwriter

given the 23 percent placebo-adjusted efficacy in these patients and the vastly improved safety over biologics," wrote Piper Jaffray analyst Ian Somaiya